Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04799704 Completed - Covid19 Clinical Trials

Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.

Eye-Covid
Start date: September 11, 2020
Phase:
Study type: Observational

To investigate the presence of SARS-nCoV-2 in the tear film of symptomatic and pauci-symptomatic SARS-nCoV-2 positive patients.

NCT ID: NCT04799691 Completed - COVID-19 Clinical Trials

Comparison of 2 Ventilatory Support Strategies During Coronavirus Disease 2019 (Covid-19) Pneumonia

STRATIC
Start date: February 1, 2021
Phase:
Study type: Observational

This retrospective monocentric study compares 2 ventilatory support strategies on outcomes (length of stay, intubation, mortality) in patients admitted in Intensive Care Unit with Covid-19 related pneumonia : invasive strategy used during the first period and non-invasive strategies (Continuous Positive Airway Pressure, High Flow Nasal Canula, Prone Position) used during the second period.

NCT ID: NCT04799652 Completed - Covid19 Clinical Trials

Are Surgeons Ready to Get the COVID-19 Vaccine?

Start date: January 15, 2021
Phase:
Study type: Observational

The COVID-19 pandemic continues to rage and most of the world is facing a second wave with continuous lockdown and strict measures aiming to control it. While vaccination is on its way, and has even started in several countries, trust and acceptance remain a challenge for an effective vaccination strategy, especially with the increasing vaccination hesitance in recent years . It is important to understand the main concerns towards the COVID-19 vaccine so they can be addressed in a constructive way - more specifically among health care professionals who are at the frontline of the pandemic. The aim of this study is to evaluate whether surgeons are ready for the COVID-19 vaccine and to understand their main concerns towards the vaccine. In an objective to evaluate the attitude of doctors towards the COVID vaccine and the effect of prolonged lockdown on their psychological burden, the investigators created an anonymous survey of 21 questions.

NCT ID: NCT04799600 Completed - COVID19 Clinical Trials

The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU

Start date: September 1, 2020
Phase:
Study type: Observational

Aim of the study is to determinate the frequency of acute renal failure in COVID-19 patients, its relationship with the severity of COVID-19 disease in ICU, and the ability to take precautions against these factors.

NCT ID: NCT04799444 Recruiting - Covid19 Clinical Trials

LATE-COVID/LATE-COVID-Kids - Observational Study in Children and Adults

LATE-COVID
Start date: October 1, 2020
Phase:
Study type: Observational [Patient Registry]

All consecutive patients admitted to the Polish Mother Memorial Research Institute (PMMHRI) in Lodz, Poland between 1st October 2020 and 31st December 2021 due to symptoms, which might reflect complications following COVID-19, will be included in the observational cohort study. Data concerning clinical characteristics, results of laboratory tests, other studies, such as: echocardiography, 24 hours ambulatory ECG recording will be collected. The study is planned also to be extended with the genetic predisposition in children to COVID-19 late complications (within independent grant).

NCT ID: NCT04799392 Terminated - COVID-19 Clinical Trials

NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human fingerstick whole blood at the Point of Care (POC); i.e. in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation; and at home.

NCT ID: NCT04799132 Completed - Obesity Clinical Trials

Association Between Body Mass Index and HFNC Therapy Success

Start date: March 11, 2020
Phase:
Study type: Observational

Patients over 18 years of age who are admitted to the Intermediate Care Unit of the Clinica del Country and the Clinica la Colina, with symptoms suggestive of severe pneumonia secondary to COVID-19 infection and acute hypoxemic respiratory failure. The primary outcome will be to determine the relationship between body mass index and high-flow cannula therapy success defined as: No need for mechanical ventilation.

NCT ID: NCT04798716 Not yet recruiting - Covid19 Clinical Trials

The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19

ARDOXSO
Start date: September 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Novel coronavirus pneumonia (NCP) and acute respiratory distress syndrome (ARDS) are both associated with the prevailing upper respiratory tract infections caused by the RNA-containing SARS-CoV2 virus of the genius Betacoronavirus of the Coronaviridae family. As both the viral infiltration and infection progress, the host immune system response can be one of a rapidly developing fatal cytokine storm. In the ARDS or NCP ensuing progression, the patient often succumbs to the effects of the hyper pro-inflammatory response, hence contributing to the associated increased mortality as a result of the cytokine storm and associated pathogenesis.

NCT ID: NCT04798677 Completed - Covid19 Clinical Trials

Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

Start date: October 29, 2020
Phase: N/A
Study type: Interventional

The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions. Innate immunity can adapt and respond more efficiently to secondary exposures, thanks to epigenetic and metabolic reprogramming, namely "trained immunity". ABBC1 is a combination of beta-1,3/1,6-glucan with inactivated Saccharomyces cerevisae rich in selenium and zinc for training immunity. ABBC1 includes repurposed synergistic yeast-based ingredients: a unique ß-1,3/1,6-glucan complex and a consortium of probiotic Saccharomyces cerevisiae, rich in Selenium and Zinc. ABBC1 induces trained immunity due to its specific chemical and tridimensional structure: its ß-glucan complex interacts with specific receptors in immune cells, provoking a release of cytokines and priming phagocytosis. Simultaneous activation of these pathways activates innate immunity and counteracts cytokine storm. ABBC1 provides highly bioavailable selenium and zinc, micronutrients with a critical role in an optimal immune responsiveness to allergy, infection, and vaccines. ABBC1 possesses proven microbiome modulating properties, which revert in immune training. Due to its high tolerance, safety and immediate availability, ABBC1 is an ideal candidate for complementary management of geriatric patients with seasonal influenza viruses or COVID-19, or to improve the immune response in the general population receiving the influenza or Covid-19 vaccines. The absence of drug interactions in ABBC1 allows a dosage that is fully compatible with the medication prescribed for all types of patients, including the elderly who are frequently polymedicated, and allows adding an additional therapeutic tool in the fight against the pandemic. This study assesses the benefits of a nutritional supplementation with ABBC1 in volunteers receiving the influenza vaccine during autumn 2020 and the Covid-10 vaccine during winter 2021.

NCT ID: NCT04798066 No longer available - Clinical trials for Post COVID-19 Syndrome

Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome

Start date: n/a
Phase:
Study type: Expanded Access

This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care.